ZOLPIDEM TARTRATE (zolpidem tartrate) by Almatica Pharma is short-term treatment of insomnia through binding to the benzodiazepine site of α1 subunit containing gaba a receptors, increasing the frequency of chloride channel opening resulting in the inhibition of neuronal excitation. Approved for insomnia. First approved in 2007.
Drug data last refreshed 19h ago
short-term treatment of insomnia through binding to the benzodiazepine site of α1 subunit containing GABA A receptors, increasing the frequency of chloride channel opening resulting in the inhibition of neuronal excitation.
Residual Effects of Zolpidem Tartrate Extended Release and Eszopiclone Vs Placebo
Zolpidem Tartrate 10 mg Tablets Under Non-Fasting Conditions
Zolpidem Tartrate 10 mg Tablets Under Fasting Conditions
Worked on ZOLPIDEM TARTRATE at Almatica Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.